

Ukraine's Ministry of Health submits proposal to the government on expanded use of osseointegration in healthcare

Mölnådal, Sweden, 29 June 2026 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) announces that Ukraine's Ministry of Health (MOZ) has completed the preparatory phase of the proposal to introduce osseointegration as part of the national treatment of amputees. The proposal is now being forwarded to the Cabinet of Ministers for a government decision.

In early 2026, the Ukrainian government adopted a roadmap to reform the country's infrastructure for prosthetic treatment. At a high-level coordination meeting in April, attended by the Minister of Health, the Minister of Social Policy and the head of the National Health Service of Ukraine (NSZU), among others, a working group was established to prepare the pilot project and gather opinions from the relevant consultation bodies on the matter. The assessment now presented marks the conclusion of the working group's preparatory work, in which the consultation bodies' opinions have been reviewed and processed. The agency is now submitting the basis for the decision to the government's secretariat for further preparation. The government is expected to be in a position to decide on the financial and executive structure of the project.

"The decision by Ukraine's Ministry of Health to advance the proposal to make osseointegration part of Ukraine's public healthcare toward a binding government decision is very positive. It strengthens the recognition of the method as an established treatment and may, over time, give more amputees access to care with the OPRA® Implant System. We continue to follow the process closely and stand ready to support the country's healthcare providers and patients," says Martin Hillsten, CEO of Integrum.

Integrum's OPRA® has been used in approximately 100 osseointegration procedures in Ukraine since 2023. The company has established Centers of Excellence in Kyiv and Cherkasy; Dr Rickard Brånemark has been central to building the company's presence in the country and continues to support the clinical training of the country's surgeons; and in April 2026 the company recruited a business manager to coordinate its operations in the country. A state-funded pilot project would expand Integrum's addressable market and contribute to broader recognition of osseointegration as an established treatment method.

For background, read the interview with Victoria Boiko, Business Development Lead, at [Integrum Investor News](#).

For more information, please contact:

Martin Hillsten, CEO

Tel: +46 733 55 28 32

Email: martin.hillsten@integrum.se

Certified Adviser

DNB Carnegie Investment Bank AB (publ)
+46 8-588 685 70
certifiedadviser@dnbcarnegie.se

About Us

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore eliminating the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit <https://integrum.se/>.